Zura Bio Appoints Eisner and Nirula to Board Effective Feb. 21, 2026
Zura Bio appointed Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors effective February 21, 2026. Both leaders bring extensive drug development experience in autoimmune and inflammatory diseases to support the company’s clinical-stage pipeline.
1. Board Appointments
Zura Bio has appointed Mark Eisner, M.D., M.P.H., and Ajay Nirula, M.D., Ph.D., to its Board of Directors effective February 21, 2026, expanding its leadership team with seasoned drug development executives.
2. Strategic Impact
Eisner and Nirula bring deep expertise in autoimmune and inflammatory therapeutic development, aiming to strengthen oversight and accelerate progress across Zura Bio’s clinical-stage pipeline.
Related News
BCS
Samsung Electronics Agrees 40 Trillion Won Bonus Package for Chip Workers
BCS•
GIB
CGI Adds Governed AI Guidance, Natural-Language Queries and Agentic Workflow to Advantage ERP
GIB•
GILD
Gilead Launches Five-Year WHO Collaboration with $9.2M Aid and 400,000 AmBisome Vials
GILD•
NVDA
NVIDIA Forecasts Zero China Data Center Revenue, Targets $20B Vera CPU Sales
NVDA•
UXIN
Uxin to Launch 5,000-Vehicle Chongqing Superstore in 2026 Expansion Drive
UXIN•
Sources
BB